Onco-Innovations Appoints Dr. Islam Mohamed as Scientific Advisory Board Chair to Advance Oncology Pipeline
Key Insights
Onco-Innovations Limited (search) has appointed Dr. Islam Mohamed, an experienced radiation oncologist and clinical researcher, as Chair of its Scientific and Clinical Advisory Board to strengthen its clinical leadership capabilities.
Dr. Mohamed brings over two decades of experience in oncology innovation, having led numerous clinical trials in breast, lung, and oligometastatic cancers while serving on research ethics boards and national clinical trial committees.
The appointment reflects the company's commitment to advancing its oncology pipeline and translational research initiatives, with Dr. Mohamed's expertise in stereotactic radiation delivery and biotech investment expected to guide strategic R&D decisions.
Onco-Innovations Limited (search) has strengthened its clinical leadership with the appointment of Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board, marking a strategic move to advance the company's oncology pipeline and translational research initiatives.
Clinical Expertise and Research Leadership
Dr. Mohamed brings over two decades of experience operating at the intersection of oncology and innovation. After earning an Honours BSc in Genetics, he completed his specialty training in Radiation Oncology in 2000. At BC Cancer (search), he has built a distinguished clinical career focused on lung, breast, skin cancers, and sarcoma, with recognized expertise in stereotactic radiation delivery.
The newly appointed chair has led numerous clinical trials at both local and provincial levels, contributing to advances in the treatment of breast, lung, and oligometastatic cancers. His research leadership extends to serving on research ethics boards and national clinical trial committees, where he has shaped standards of care and clinical research strategy in Canada.
Biotech Investment and Innovation Focus
Complementing his clinical leadership, Dr. Mohamed brings deep insight into the health technology ecosystem through his advisory and investment activities in emerging Canadian biotech ventures. His portfolio includes companies such as Linax Technologies (search), IllumiSonics (search), and Asep Medical (search), with a focus on transformative diagnostics, therapeutics, and platform technologies.
"His combined experience as a clinician, researcher, and entrepreneur positions him as a strategic asset in evaluating innovation, guiding translational research, and driving value creation," according to the company's announcement.
Strategic Advisory Role
The Scientific and Clinical Advisory Board plays a critical role in supporting Onco-Innovations' research and development priorities. Its mandate includes providing strategic guidance on R&D initiatives, facilitating clinical and scientific collaboration among partners, and supporting the mobilization of knowledge and generation of independent scientific insights to guide decision-making.
"We are thrilled to welcome Dr. Mohamed as Chair of our Scientific and Clinical Advisory Board. His deep clinical insight, research leadership, and strategic involvement in biotech innovation will be instrumental as we advance our oncology pipeline and translational research initiatives," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
Company Background and Technology Platform
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology solutions. The company's mission focuses on pursuing the prevention and treatment of cancer through pioneering research and innovative solutions. Notably, Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumors.
The appointment reflects the company's commitment to scientific excellence and its mission to accelerate the development of innovative oncology solutions through expert-led translational research, positioning the organization to leverage Dr. Mohamed's extensive clinical and entrepreneurial experience in advancing its therapeutic development programs.